The KIF20A-derived peptide vaccine induced high numbers of IFN-γ-producing cells, even in patients treated with GEM, suggesting this combination therapy holds promise for advanced pancreatic cancer. The gene discussed is IFNG; the disease is familial pancreatic carcinoma.